AngioDynamics (ANGO) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

3 analysts have issued 1 year price targets for AngioDynamics' shares. Their ANGO share price forecasts range from $13.00 to $20.00. On average, they expect the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 135.5% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $13.77 on January 1st, 2023. Since then, ANGO stock has decreased by 46.6% and is now trading at $7.36.
View the best growth stocks for 2023 here.

AngioDynamics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,850,000 shares, an increase of 51.6% from the August 31st total of 1,220,000 shares. Based on an average daily trading volume, of 650,100 shares, the short-interest ratio is currently 2.8 days. Approximately 4.9% of the shares of the stock are short sold.
View AngioDynamics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our ANGO earnings forecast.

AngioDynamics will be holding an earnings conference call on Wednesday, October 4th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13741149".

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The medical instruments supplier earned $91.10 million during the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative net margin of 15.48% and a negative trailing twelve-month return on equity of 0.61%. The business's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.01 EPS.

AngioDynamics issued an update on its FY 2024 earnings guidance on Thursday, July, 13th. The company provided EPS guidance of -$0.34--$0.28 for the period, compared to the consensus EPS estimate of -$0.02. The company issued revenue guidance of $328.00 million-$333.00 million, compared to the consensus revenue estimate of $353.62 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.62%), Dimensional Fund Advisors LP (5.35%), State Street Corp (4.51%), Victory Capital Management Inc. (3.67%), The Manufacturers Life Insurance Company (2.29%) and Paradigm Capital Management Inc. NY (2.05%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANGO stock can currently be purchased for approximately $7.36.

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $291.97 million and generates $338.75 million in revenue each year. The medical instruments supplier earns $-52,440,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

The company employs 815 workers across the globe.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.